Abstract:Cytochrome P450 3A4 (CYP3A4), a key enzyme, is pivotal in metabolizing approximately half of the drugs used clinically. The genetic polymorphism of the CYP3A4 gene significantly influences individual variations in drug metabolism, potentially leading to severe adverse drug reactions (ADRs). In this study, we conducted a genetic analysis on CYP3A4 gene in 1163 Chinese Han individuals to identify the genetic variations that might affect their drug metabolism capabilities. For this purpose, a multiplex polymerase chain reaction (PCR) amplicon sequencing technique was developed, enabling us to perform the genotyping of CYP3A4 gene efficiently and economically on a large scale. As a result, a total of 14 CYP3A4 allelic variants were identified, comprising six previously reported alleles and eight new nonsynonymous variants that were nominated as new allelic variants *39–*46 by the PharmVar Association. Further, functional assessments of these novel CYP3A4 variants were undertaken by coexpressing them with cytochromes P450 oxidoreductase (CYPOR) in Saccharomyces cerevisiae microsomes. Immunoblot analysis indicated that with the exception of CYP3A4.40 and CYP3A4.45, the protein expression levels of most new variants were similar to that of the wild-type CYP3A4.1 in yeast cells. To evaluate their catalytic activities, midazolam was used as a probe drug. The results showed that variant CYP3A4.45 had almost no catalytic activity, whereas the other variants exhibited significantly reduced drug metabolism abilities. This suggests that the majority of the CYP3A4 variants identified in the Chinese population possess markedly altered capacities for drug metabolism. SIGNIFICANCE STATEMENT In this study, we established a multiplex polymerase chain reaction (PCR) amplicon sequencing method and detected the maximum number of new CYP3A4 variants in a single ethnic population. Additionally, we performed the functional characterizations of these eight novel CYP3A4 allele variants in vitro. This study not only contributes to the understanding of CYP3A4 genetic polymorphism in the Chinese Han population but also holds substantial reference value for their potential clinical applications in personalized medicine.

Effect of CYP2C19 genetic polymorphism on pharmacokinetic characterstics and 5-hydroxyl metabolic pathway of lansoprazole in Chinese volunteers

Effect of CYP2C19 Genetic Polymorphism on Lansoprazole Pharmacokinetics:A Systematic Review

Effects of Cyp2c19 Polymorphism on the Pharmacokinetics of Lansoprazole and Its Main Metabolites in Healthy Chinese Subjects

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Influence of Cytochrome P450 2C19 on the Pharmacokinetics of Lansoprazole Administered by Single and Successive Intravenous Infusion in Healthy Chinese Volunteers

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Effects of CYP2C19 polymorphism on pharmacokinetic profile and comparative bioavailability of omeprazole

Effect of Cytochrome P450(CYP)3A5, CYP2C19 Gene Polymorphism on Pharmacokinetic Characteristics of Voriconazole in Chinese Healthy Volunteers

Evaluation of the Relationship Between Polymorphisms in CYP2C19 and the Single‐dose Pharmacokinetics of Omeprazole in Healthy Chinese Volunteers: A Multicenter Study

Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers

Effect of the CYP2C19 Oxidation Polymorphism on Fluoxetine Metabolism in Chinese Healthy Subjects

Pharmacokinetics of Lansoprazole and Its Main Metabolites after Single and Multiple Intravenous Doses in Healthy Chinese Subjects.

Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole

Influence of CYP2D6 Genetic Polymorphism on Pharmacokinetics of Paroxetine in Chinese Healthy People

Pharmacokinetics of the New Proton Pump Inhibitor Ilaprazole in Chinese Healthy Subjects in Relation to CYP3A5 and CYP2C19 Genotypes.

Analyses of the Phenotype Polymorphism of Cytochrome CYP2C19in Chinese Han

Relationship between the CYP2C19 polymorphism and the efficacy of triple therapy with lansoprazole onHelicobacter pylori infection in elderly patients

Genetic Polymorphisms and Phenotypic Analysis of Drug-Metabolizing Enzyme CYP2C19 in a Li Chinese Population.

Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy

Effect of Polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the Pharmacokinetics of Lovastatin in Healthy Chinese Volunteers.